

PHARMACEUTICAL POLICY IN AUSTRALIA:
DEVELOPING METHODS TO MANAGE
UNCERTAINTY IN HEALTH TECHNOLOGY
ASSESSMENT

Bonny Tina Parkinson

A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy.

Faculty of Business

University of Technology, Sydney

2015

CERTIFICATE OF ORIGINAL AUTHORSHIP

I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as fully acknowledged within the text.

I also certify that the thesis has been written by me. Any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

Signature of Student:

Date:

ACKNOWLEDGEMENTS

This thesis has been a learning process – an ‘apprenticeship in research’. It has been an enjoyable and fascinating experience, but at times challenging and frustrating. I have many people to thank for helping me along the way.

I would like to thank my supervisors, Professor Rosalie Viney, Associate Professor Stephen Goodall and Professor Marion Haas for their guidance, encouragement, reassurance, understanding, and late nights spent reading countless drafts. They constantly challenged my ideas and I think the thesis is all the better for it. I will be forever grateful for the knowledge they have imparted.

I am also lucky to have received advice and encouragement from many other people, both within the Centre for Health Economics Research and Evaluation (CHERE) and at other universities. In particular, I would like to thank Liz Chinchin for her editorial assistance and for identifying things I would have otherwise missed. Thank you to Associate Professor Sallie-Anne for enabling access to the Herceptin Program data and on her advice on how to interpret it. Thank you to Dr Rebecca Reeve, Dr Preeyaporn Srasuebkul and Professor Denzil Fiebig for their advice regarding the statistical and econometric analyses, and to Dr Phil Haywood and Dr Deme Karikios for their clinical input into various chapters. Plus a further thank you to Sallie and Phil for their constant encouragement and positivity.

Thank you to the members of the PhD group and CHERE for their useful feedback given at numerous seminars, and to all the participants at the Australian Health Economics Society conferences in 2011, 2012, 2013 and 2014, at the International Health Economics Association conference in 2013, and the International Society for Pharmacoeconomics and Outcomes Research conference in 2013.

Thank you to Jody Church for her immeasurable friendship, for listening and the occasional hug. Thank you to Mum, Dad, Chloe, Scott, Don, Lewis and Leonard for providing me somewhere safe to run and hide.

Finally, thank you to Vesa for his constant support and understanding. I love you more than words can say.

ATTRIBUTION STATEMENT FOR ARTICLE PUBLISHED IN THE EUROPEAN JOURNAL OF HEALTH ECONOMICS

I (Bonny Parkinson) conducted the literature review, analysed and critiqued the evaluations, and was the key author of the paper. Associate Professor Sallie-Anne Pearson was involved in the inception of the paper. Associate Professor Sallie-Anne Pearson and Professor Rosalie Viney provided comments on the draft versions of the paper, focusing on style and structure.

A copy of the article published in the European Journal of Health Economics is presented in Appendix 1.

FUNDING

The research reported in this thesis is supported by an Australian NHMRC Capacity Building Grant in Health Services Research.

ETHICS

The analysis of the Herceptin Program data was approved by the NSW Population & Health Services Research Ethics Committee (protocol HREC/10/CIPHS/11), the Medicare Australia External Request Evaluation Committee (2010/CO07329), and is a part of a research program approved by the University of Technology Sydney Research Ethics Committee (UTS HREC REF NO. 2009-143P).

TABLE OF CONTENTS

1.	INTRODUCTION.....	1
1.1.	Introduction.....	1
1.2.	Aims and objectives.....	3
1.3.	Description of case study: trastuzumab for the treatment of HER2+ metastatic breast cancer 4	
1.4.	Overview of the structure of the thesis.....	6
2.	PHARMACEUTICAL POLICY IN AUSTRALIA.....	10
2.1.	The market for new drugs.....	10
2.2.	The Pharmaceutical Benefits Scheme.....	12
2.3.	Pharmaceutical Benefits Scheme expenditure.....	13
2.4.	The role of the Pharmaceutical Benefits Advisory Committee.....	17
2.4.1.	The listing process.....	17
2.4.2.	PBAC guidelines.....	20
2.4.3.	Drivers of recommendations by the PBAC.....	22
2.5.	Managing utilisation and costs.....	25
2.5.1.	Managing the utilisation and costs of new, on-patent drugs.....	25
2.5.2.	Managing the utilisation and costs of older, off-patent drugs.....	28
2.5.3.	Interaction between the PBS and other sectors of the health system.....	34
2.6.	Conclusion.....	37
3.	MANAGING RISK IN FUNDING DECISIONS.....	39
3.1.	Introduction.....	39
3.2.	The limitations of randomised controlled clinical trials.....	40
3.3.	Economic modelling.....	44
3.4.	Characterising uncertainty.....	48
3.5.	Managing uncertainty.....	49
3.5.1.	Lower price.....	50
3.5.2.	Restrictions.....	50
3.5.3.	Delay.....	50
3.5.4.	Risk-sharing arrangements.....	51
3.6.	When to conduct additional research.....	56
3.6.1.	Current funding decision algorithm used by the PBAC.....	57
3.6.2.	Proposed funding decision algorithm incorporating CED recommendations.....	58
3.7.	Conclusion.....	69

4. ECONOMIC EVALUATIONS OF TRASTUZUMAB IN HER2+ METASTATIC BREAST CANCER: A SYSTEMATIC REVIEW AND CRITIQUE.....	71
4.1. Introduction.....	71
4.2. Methods.....	72
4.3. Results.....	73
4.3.1. Search results	73
4.3.2. Efficacy.....	74
4.3.3. Data synthesis	77
4.3.4. Testing for HER2+, comparators and treatment regimens.....	78
4.3.5. Adjustments to efficacy estimates.....	79
4.3.6. Adverse events	80
4.3.7. Utilities.....	81
4.3.8. Costs.....	83
4.3.9. Reporting of results and author conclusions	87
4.4. Discussion	91
4.5. Conclusion	94
5. AN ECONOMIC EVALUATION OF TRASTUZUMAB IN HER2+ METASTATIC BREAST CANCER: USING STANDARD METHODS.....	96
5.1. Introduction.....	96
5.2. The evidence considered by the PBAC in 2000, 2001 and 2008.....	98
5.3. Methods.....	103
5.3.1. Target population	108
5.3.2. HER2 testing.....	109
5.3.3. Efficacy.....	111
5.3.4. Adverse events	115
5.3.5. Utilities and disutilities	117
5.3.6. Costs.....	125
5.3.7. Model validation	131
5.3.8. Sensitivity analysis.....	133
5.4. Results.....	147
5.4.1. Base case deterministic results.....	147
5.4.2. Univariate sensitivity analysis	150
5.4.3. Scenario analysis.....	153
5.4.4. Sub-group analysis.....	158
5.4.5. Threshold analysis	159
5.4.6. Probabilistic sensitivity analysis	160

5.5.	Discussion	163
5.5.1.	Comparison with the 2008 PBAC review and other published economic evaluations	163
5.5.2.	Strengths of the approach used in this chapter	164
5.5.3.	Limitations of the approach used in this chapter.....	165
5.6.	Conclusion	167
6.	THE VALUE OF CONDUCTING FURTHER RESERCH	168
6.1.	Introduction.....	168
6.2.	Methods.....	170
6.2.1.	The observational data	170
6.2.2.	Best-case scenario analysis	171
6.2.3.	Value of information analysis	171
6.3.	Results.....	179
6.3.1.	Best-case scenario analysis	179
6.3.2.	Value of information analysis	179
6.4.	Discussion	182
6.4.1.	Policy implications.....	182
6.4.2.	Strengths of the approach used in this chapter	184
6.4.3.	Limitations of the approach used in this chapter.....	185
6.5.	Conclusion	191
7.	REAL-WORLD OBSERVATIONAL DATA OF TRASTUZUMAB IN HER2+ METASTATIC BREAST CANCER.....	192
7.1.	Introduction.....	192
7.2.	Methods.....	194
7.2.1.	Data sources	194
7.2.2.	Included and excluded patients	195
7.2.3.	Patient characteristics.....	196
7.2.4.	Resource use in clinical practice	196
7.2.5.	Health outcomes in clinical practice	204
7.3.	Results.....	205
7.3.1.	Included and excluded patients	205
7.3.2.	Descriptive statistics	206
7.3.3.	Resource use in clinical practice	208
7.3.4.	Health outcomes in clinical practice	222
7.4.	Health outcomes and resource use in Australian clinical practice compared to that observed in clinical trials and treatment guidelines	224
7.5.	Discussion	231

7.5.1.	Strengths of the approach used in this chapter	232
7.5.2.	Limitations of the approach used in this chapter.....	233
7.5.3.	Policy implications.....	236
7.6.	Conclusion	237
8.	COST-EFFECTIVENESS OF TRASTUZUMAB FOR HER2+ METASTATIC BREAST CANCER IN CLINICAL PRACTICE	238
8.1.	Introduction.....	239
8.2.	Methods.....	241
8.2.1.	Step 1: Resource use in clinical practice.....	241
8.2.2.	Step 2: Time to progression and overall survival in clinical practice	243
8.2.3.	Step 3: Treatment population in clinical practice.....	245
8.2.4.	Step 4: Accounting for clinical variation in adherence to Herceptin Program treatment guidelines.....	246
8.2.5.	Net impact of the establishment of the Herceptin Program	248
8.3.	Results.....	248
8.3.1.	Step 1: Resource use in clinical practice.....	249
8.3.2.	Step 2: Time to progression and overall survival in clinical practice	250
8.3.3.	Step 3: Treatment population in clinical practice.....	251
8.3.4.	Step 4: Accounting for non-adherence of clinicians to Herceptin Program treatment guidelines.....	252
8.3.5.	Net impact of the establishment of the Herceptin Program	253
8.4.	Discussion	253
8.5.	Conclusion	257
9.	DISCUSSION	258
9.1.	Key messages.....	258
9.2.	Policy implications.....	260
9.3.	Future research.....	267
10.	Conclusion.....	268
11.	Appendices.....	269
11.1.	Appendix 1: European Journal of Health Economics article	269
11.2.	Appendix 2: Co-payments and brand premiums.....	270
11.3.	Appendix 3: Case studies	272
11.3.1.	Bosentan for the treatment of idiopathic pulmonary arterial hypertension in Australia	272
11.3.2.	Hyperbaric oxygen therapy in Australia	272
11.3.3.	Beta interferons and glatiramer acetate for the treatment of multiple sclerosis	275

11.4.	Appendix 4: Decision algorithm developed by Claxton et al. (2012).....	276
11.5.	Appendix 5: Detailed results of trastuzumab review	278
11.6.	Appendix 6: Review of Markov model structures	280
11.7.	Appendix 7: Parameter values used in the 2013 economic model.....	281
11.8.	Appendix 8: Parameter values used in the 2001 economic model that differ from the 2013 economic model	292
11.9.	Appendix 9: Analysis of Kaplan-Meier curves.....	297
11.10.	Appendix 10: CHEERS statement	303
11.11.	Appendix 11: PSA results	305
11.12.	Appendix 12: Standard error calculations.....	306
12.	REFERENCES.....	308

LIST OF TABLES

Table 2-1: Example of PBS listing	13
Table 2-2: Summary of the PBAC guidelines	20
Table 2-3: Drivers of recommendations by the PBAC	24
Table 2-4: Chemotherapy separations.....	36
Table 3-1: Strengths and weaknesses of real-world observational data.....	66
Table 4-1: Summary of economic evaluations of trastuzumab for the treatment of HER2+ metastatic breast cancer.....	74
Table 4-2: Efficacy estimates applied in economic evaluations of trastuzumab	75
Table 4-3: Design and synthesis methods used by economic evaluations of trastuzumab	78
Table 4-4: Adverse events included in economic evaluations of trastuzumab	81
Table 4-5: Utilities and disutilities applied in economic evaluations of trastuzumab	83
Table 4-6: Resource use and costs applied in economic evaluations of trastuzumab	85
Table 4-7: Results of the economic evaluations of trastuzumab.....	88
Table 4-8: Sensitivity analyses	90
Table 5-1: Summary of RCTs regarding trastuzumab for the first-line treatment of HER2+ metastatic breast cancer	101
Table 5-2: Overall response by testing strategy, sub-analysis of trial H0648g.....	105
Table 5-3: HER2 status classification according to test strategy*	109
Table 5-4: Studies reporting HER2 testing results published on or before 2001.....	110
Table 5-5: Treatment effects measured by H0648g, paclitaxel arms.....	111
Table 5-6: Goodness of fit of parametric functions to overall survival in trial H0648g, paclitaxel treatment arms.....	114
Table 5-7: Metastatic breast cancer meta-regression of utility values by Peasgood et al. (2010) ...	118
Table 5-8: Metastatic breast cancer mixed model analysis by Lloyd et al. (2006).....	119
Table 5-9: Metastatic breast cancer meta-regression by Frederix et al. (2013), Netherlands sub-group	119
Table 5-10: Disutilities associated with adverse events in the literature, mean (SE)	121
Table 5-11: Disutilities associated with adverse events from Fryback et al. (1993)	122
Table 5-12: Studies that estimate utility values associated with metastatic breast cancer health states published on or before 2001	123
Table 5-13: Proportion of chemotherapy episodes in each setting	126
Table 5-14: Chemotherapy details in trial H0648g, paclitaxel treatment arms	126
Table 5-15: Chemotherapy details: second-line therapy.....	130
Table 5-16: Economic model definitions.....	133
Table 5-17: Treatment effects measured by the clinical trials	135
Table 5-18: Goodness of fit of parametric functions	136
Table 5-19: Chemotherapy details in all clinical trials	137
Table 5-20: Parametric distributions used for probabilistic sensitivity analysis.....	147
Table 5-21: Health outcomes in Model 1.....	147
Table 5-22: Health outcomes in Model 1.....	148
Table 5-23: Costs in Model 1 (\$).....	149
Table 5-24: ICER in Model 1	149

Table 5-25: Health outcomes by model in 2001 and 2013	153
Table 5-26: ICER by model	154
Table 5-27: ICER by model with trastuzumab continued post-progression	155
Table 5-28: Deterministic versus probabilistic ICERs (\$/QALY gained) – Model 1, best-available data in 2001	161
Table 5-29: Differences between the PBAC review and the analysis presented in this chapter	163
Table 6-1: Resource use and health outcome parameters collected through observational data	170
Table 6-2: How to measure EVPI, EVPPI and EVSI using a Monte Carlo simulation approach	176
Table 6-3: Example of how to estimate the EVPI.....	176
Table 6-4: ICER in Model 1 – best-case scenario, best-available data in 2001	179
Table 7-1: Data contained in each file	194
Table 7-2: ATC codes used to identify concomitant therapies^	199
Table 7-3: Explanatory variables	201
Table 7-4: MBS items numbers used to identify resource use.....	203
Table 7-5: Descriptive statistics of patients enrolled in the Herceptin Program and included in this analysis.....	206
Table 7-6: Weight of patients enrolled in the Herceptin Program and included in this analysis, by age	207
Table 7-7: Number of 150mg vials by age and by trastuzumab regimen, based on Herceptin Program data	208
Table 7-8: Total treatment duration with trastuzumab, based on Herceptin Program data.....	209
Table 7-9: Chemotherapies administered prior to treatment with trastuzumab, based on Herceptin Program data	210
Table 7-10: All concomitant chemotherapies administered, based on Herceptin Program data	213
Table 7-11: Concomitant chemotherapies administered, based on Herceptin Program data, details	213
Table 7-12: Duration of treatment with initial concomitant chemotherapies, based on Herceptin Program data	214
Table 7-13: Chemotherapies administered after disease progression estimated based on the Herceptin Program data and compared to that applied in the economic model.....	215
Table 7-14: Factors influencing whether trastuzumab was administered only as a monotherapy	218
Table 7-15: Factors influencing which concomitant chemotherapies were administered	218
Table 7-16: Medical services received based on Herceptin Program data compared to that applied in the economic model	221
Table 7-17: TTP and PFS based on Herceptin Program data compared to that reported in the clinical trials and applied in the economic model.....	223
Table 7-18: Overall survival based on Herceptin Program data compared to that reported in the clinical trials and applied in the economic model.....	224
Table 8-1: Steps used to estimate the cost-effectiveness of trastuzumab for HER2+ metastatic breast cancer in clinical practice.....	241
Table 8-2: Changes to resource use parameters to reflect clinical practice	242
Table 8-3: Changes to PFS and overall survival to reflect clinical practice	245
Table 8-4: Age group weightings.....	246

Table 8-5: Key concomitant chemotherapies administered pre-progression to patients in Herceptin Program.....	247
Table 8-6: Changes reflecting treatment with trastuzumab post-progression.....	248
Table 8-7: ICER by model without Herceptin Program data, best available in 2013.....	248
Table 8-8: Step 1: Resource use in clinical practice, ICER by model.....	249
Table 8-9: Step 1 to 2: time to progression and overall survival in clinical practice, health outcomes by model.....	251
Table 8-10: Step 1 to 2: time to progression and overall survival in clinical practice, ICER by model.....	251
Table 8-11: Step 1 to 3: treatment population in clinical practice, weighted average ICER by model.....	252
Table 8-12: Weighted average ICER by model: Step 4.....	252
Table 8-13: Weighted average ICER by model: Step 4.....	253
Table 11-1: History of PBS co-payments and safety net thresholds.....	270
Table 11-2: Detailed results of economic evaluations of trastuzumab.....	278
Table 11-3: HER2 testing.....	281
Table 11-4: Probability of response, stable disease and ORs.....	281
Table 11-5: Coefficients for fitted parametric functions.....	282
Table 11-6: Median TTP and overall survival, with chemotherapy alone.....	282
Table 11-7: HRR of TTP and overall survival, trastuzumab + chemotherapy.....	283
Table 11-8: Annual probability of death from other causes.....	284
Table 11-9: Probability of grade 3/4 adverse events, chemotherapy alone (beta distributions).....	285
Table 11-10: Odds ratios of grade 3/4 adverse events, trastuzumab + chemotherapy (log-normal distributions).....	286
Table 11-11: Utilities and disutilities associated with adverse events.....	288
Table 11-12: Drug costs per week (\$A2012-13).....	289
Table 11-13: Other resource parameters.....	290
Table 11-14: MBS fees for specialist visits, drug administration and monitoring (\$A2012-13).....	290
Table 11-15: Other cost parameters (\$A2012-13).....	291
Table 11-16: HER2 testing.....	292
Table 11-17: Annual probability of death from other causes.....	292
Table 11-18: Utilities and disutilities associated with adverse events.....	293
Table 11-19: Drug costs per week (\$A2001).....	294
Table 11-20: Other resource parameters.....	295
Table 11-21: MBS fees for specialist visits, drug administration and monitoring (\$A2001).....	295
Table 11-22: Other cost parameters (\$A2000-01).....	296
Table 11-23: Coefficients of fitted exponential function to TTP and overall survival.....	297
Table 11-24: Coefficients of fitted Weibull function to TTP and overall survival.....	297
Table 11-25: Coefficients of fitted log-logistic function to TTP and overall survival.....	297
Table 11-26: Coefficients of fitted log-normal function to TTP and overall survival.....	297
Table 11-27: Coefficients of fitted gamma function to TTP and overall survival.....	297
Table 11-28: Coefficients of fitted Gompertz function to TTP and overall survival.....	297
Table 11-29: CHEERS statement.....	303

LIST OF ILLUSTRATIONS

Figure 1-1: Structure of this thesis	9
Figure 2-1: Total drug expenditure by type of drug, 2012-13	14
Figure 2-2: Total drug expenditure by who pays, including over-the-counter drugs, 2012-13	15
Figure 2-3: Total drug expenditure by who pays, excluding over-the-counter drugs, 2012-13.....	15
Figure 2-4: Growth in expenditure on PBS/RPBS.....	16
Figure 2-5: Growth in average benefit paid (\$) per PBS/RPBS prescription	17
Figure 2-6: Process of listing on PBS schedule	19
Figure 2-7: Incremental cost-effectiveness plane	23
Figure 2-8: PBS services by patient type, 2013	27
Figure 2-9: Ratio of the Australian price to US price for most prescribed PBS items in Australia...29	
Figure 2-10: The market for statins in Australia versus England	29
Figure 2-11: Brand premiums and prescriptions dispensed with a brand premium (where generics are available), 1994 to 2012-13.....	32
Figure 3-1: Diagrammatic representations of decision trees and state transition models	46
Figure 3-2: Types of risk-sharing arrangements	51
Figure 3-3: Current funding decision algorithm used by the PBAC.....	58
Figure 3-4: Revised algorithm incorporating CED recommendations for when the drug is cost-effective	61
Figure 3-5: Revised algorithm incorporating CED recommendations for when the drug is not cost-effective	62
Figure 4-1: Results of the economic evaluations of trastuzumab	90
Figure 5-1: Economic model of trastuzumab for the treatment of HER2+ metastatic breast cancer	107
Figure 5-2: Probabilistic Sensitivity Analysis	145
Figure 5-3: Trace of patients though Markov health states – Model 1	148
Figure 5-4: Univariate sensitivity analysis – Model 1	152
Figure 5-5: Scenario analysis – extrapolation methods, best-available data in 2001	156
Figure 5-6: Scenario analysis – extrapolation methods, best-available data in 2013	157
Figure 5-7: Scenario analysis – efficacy, best-available data in 2001	157
Figure 5-8: Scenario analysis – efficacy, best-available data in 2013	157
Figure 5-9: Other scenario analyses, best-available data in 2001	158
Figure 5-10: Other scenario analyses, best-available data in 2013.....	158
Figure 5-11: Sub-group analysis by age – Model 1	158
Figure 5-12: Threshold analysis of dose-cap versus price discount – Model 1, best available data in 2001	160
Figure 5-13: Scatter plot and CEAC – Model 1, best-available data in 2001.....	162
Figure 5-14: Scatter plot and CEAC – Model 1, with efficacy based on median duration adjusted for cross-over, best-available data in 2001	162
Figure 6-1: Normal distribution approach	175
Figure 6-2: Distribution of PSA results – Model 1, best-available data in 2001	175
Figure 6-3: EVPPI per patient treated with trastuzumab of collecting observational data linked to PBS and MBS data – Model 1, best-available data in 2001	181

Figure 6-4: Population EVPPI of collecting the observational data linked to PBS and MBS data – Model 1, best-available data in 2001	182
Figure 7-1: Patient flow diagram	206
Figure 7-2.....	208
Figure 7-3.....	209
Figure 7-4.....	209
Figure 7-5.....	210
Figure 7-6.....	211
Figure 7-7.....	213
Figure 7-8.....	216
Figure 7-9.....	218
Figure 7-10.....	219
Figure 7-11.....	222
Figure 7-12.....	222
Figure 7-13.....	223
Figure 8-1: Step 1: Impact of changing resource use in clinical practice, by parameter, Model 1, best available evidence in 2013.....	250
Figure 11-1: Co-payments as a proportion of disability support pension (DSP) and average weekly earnings (AWE)	271
Figure 11-2: Brand premiums as a proportion of co-payments, 1994 to 2012-13	271
Figure 11-3: Algorithm for technologies expected to be cost-effective.....	276
Figure 11-4: Algorithm for technologies not expected to be cost-effective	277
Figure 11-5: Markov model structures used in published economic evaluations	280
Figure 11-6: Hazard rates estimated from Kaplan-Meier curves.....	299
Figure 11-7: Fitted parametric functions to Kaplan-Meier curve	300
Figure 11-8: Convergence of PSA results – Model 1, best-available data in 2001	305
Figure 11-9: Convergence of PSA results – Model 1, with efficacy based on median duration adjusted for cross-over, best-available data in 2001	305

GLOSSARY

Term	Meaning
AC	Anthracycline
ACT	Australian Capital Territory
ACPM	Advisory Committee on Prescription Medicines
ATC	Anatomical Therapeutic Chemical
AE	Adverse event
AEMP	Approved ex-manufacturer price
AIHW	Australian Institute of Health and Welfare
ANZHMD	Australian and New Zealand Hyperbaric Medicine Group
ARC	Australian Research Council, Australia
AR-DRG	Australian Refined Diagnosis Related Groups
ARTG	Australian Register of Therapeutic Goods
ATAGI	Australian Technical Advisory Group on Immunisation
ATC	Anatomical therapeutic chemicals
ARC	Australian Research Council
bd	Twice daily
bDMARDs	Biological disease-modifying antirheumatic drugs
BMD	Bone mineral density
BSA	Body surface area
CADTH	Canadian Agency for Drugs and Technologies in Health
CEAC	Cost-effectiveness acceptability curve
CED	Coverage with Evidence Development
CHEERS	Consolidated Health Economic Evaluation Reporting Standards
CI	Confidence interval
CISH	Chromogenic in situ hybridization
CT	Computed tomography
CVAD	Central venous access device
DCE	Discrete choice experiment
DPMQ	Dispensed price for maximum quantity
DR	Duration of response
DSPP	Duration of survival post-progression
DUSC	Drug Utilisation Sub-Committee
EBC	Early breast cancer
ECG	Electrocardiogram
ECHO	Echocardiogram
ECOG	Eastern Cooperative Oncology Group
EDSS	Expanded disability status scale
ENBS	Expected net benefit of sampling
ER	Oestrogen receptor
ESC	Economics Sub-Committee
EVPI	Expected value of perfect information
EVPII	Expected value of perfect parameter information
EVSI	Expected value of sample information
EUC	Electrolytes, urea and creatinine
FBC	Full blood count
FDA	United States Food and Drug Administration
FISH	Fluorescence in situ hybridization
GP	General practitioner
HBOT	Hyperbaric oxygen therapy
HER2	Human epidermal growth factor receptor 2

Term	Meaning
HR	Hazard rate
HRR	Hazard rate ratio
HRS	Hazard Rate of Progression Following Stable Disease
HRP	Hazard rate of overall progression
HTA	Health technology assessment
ICER	Incremental cost-effectiveness ratio
ICSP	Intravenous Chemotherapy Supply Program
IHC	Immunohistochemistry
iPAH	Idiopathic pulmonary arterial hypertension
IPCW	Inverse Probability of Censoring Weights
ISH	In situ hybridisation
ISPOR	International Society for Pharmacoeconomics and Outcomes Research
ITT	Intent to treat
IV	Intravenous
kg	Kilograms
LFT	Liver function test
ln	Natural logarithm
LVEF	Left ventricular ejection fraction
LYG	Life years gained
MAUI	Multi-attribute utility instrument
MBC	Metastatic breast cancer
MBS	Medical Benefits Scheme
MES	Managed Entry Scheme
mg	Milligrams
MUGA	Multi gated acquisition scan
MSAC	Medical Services Advisory Committee
n	Number of patients/respondents etc
NA	Not applicable
NHMRC	National Health and Medical Research Council
NHS CRD	National health service Centre for Reviews and Dissemination
NHS EED	National health service economic evaluation database
NHS	National health service
NICE	National Institute for Health and Care Excellence
NIP	National Immunisation Programme
NPS	National Prescribing Service
NSW	New South Wales
NR	Not reported
NT	Northern Territory
OECD	Organisation for Economic Co-operation and Development
OIR	Only in research
OR	Odds ratio
OS	Overall survival
OWR	Only with research
PBAC	Pharmaceutical Benefits Advisory Committee
PBPA	Pharmaceutical Benefits Pricing Authority
PBS	Pharmaceutical Benefits Scheme
PFLY	Progression free life year
PFS	Progression free survival
PgR	Progesterone receptor
PPS	Post-Progression Survival
PSA	Probabilistic sensitivity analysis
q3w	Once three-weekly

Term	Meaning
QALY	Quality-adjusted life year
qd	Once daily
QLD	Queensland
qw	Once weekly
q3w	Once three weekly
r	Response rate
RCT	Randomised controlled clinical trial
RPBS	Repatriation Pharmaceutical Benefits Scheme
RPSFT	Rank preserving structural failure time
RRMA	Rural, remote and metropolitan areas
RR	Relative Risk
SA	South Australia
SE	Standard error
SD	Standard deviation
SMDM	Society for Medical Decision Making
TAS	Tasmania
TGA	Therapeutic Goods Administration
TTO	Time trade-off
TTP	Time to progression
UK	United Kingdom
US	United States of America
VIC	Victoria
VOI	Value of information
WA	Western Australia
WAMTC	Weighted average monthly treatment cost

ABSTRACT

Economic evaluation is a tool used by decision makers to ensure that promising high cost drugs that receive public funding are value for money. Funding decisions are inevitably based on limited data and there is always some uncertainty regarding whether the drug be cost-effective in clinical practice. An incorrect funding decision will reduce society's welfare. The aim of this thesis is to investigate and evaluate current and potential methods to assess and manage uncertainty regarding the cost-effectiveness of a drug in clinical practice.

The thesis undertakes an in-depth case study of a specific high cost drug which captures many of the features common to emerging high cost drugs: trastuzumab (Herceptin) for the treatment for human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer.

The research had five stages: 1) a systematic review and critique of published economic evaluations was conducted; 2) an economic model was developed using trial evidence; 3) uncertainty was analysed using different methods, including value of information analysis; 4) real-world observational data were analysed to inform modifications to model parameters; and 5) the model was adjusted to estimate the cost-effectiveness in clinical practice.

The systematic review demonstrated the importance of judgements made regarding the structure of the analysis and the data sources used in economic models. The cost-effectiveness of trastuzumab was estimated to be \$180,910/Quality Adjusted Life Year (QALY) gained in 2001 (when first considered for PBS-subsidy). This is above the range usually considered cost-effective. The model was used to demonstrate how to estimate the value of collecting real-world observational data to be used in economic evaluations. The case study was extended by exploring a hypothetical coverage with evidence development (CED) arrangement based on observational data collected within the Australian government's Herceptin Program. It was concluded that the hypothetical CED arrangement would not have been appropriate unless the cost of trastuzumab was reduced. The analysis of the observational data lead to policy options for achieving improved cost-effectiveness. In particular, non-adherence to treatment guidelines with respect to concomitant therapies and treatment post-progression was found. This underscores the need for post-market review. It was estimated that there was a net loss from funding trastuzumab via the Herceptin Program due to the high price of trastuzumab and non-adherence to treatment guidelines.

This thesis demonstrates some of the challenges for decision makers regarding high cost drugs with limited evidence, and offers some solutions regarding how uncertainty can be managed.